Related Experiment Video
Updated: Jan 18, 2026

Visualization of DNA Repair Proteins Interaction by Immunofluorescence
Published on: June 26, 2020
RAD51 is chromatin enriched and targetable in BRCA1-deficient cells
Min Peng1, Silviana Lee1, Hitha Gopalan Nair1
1Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Abstract:
BRCA1 mutant cancers are homologous recombination (HR) deficient, and their sensitivity to anti-cancer therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) has long been attributed to this defect. Accordingly, the HR marker, RAD51 foci have been widely used as biomarkers of PARPi response. However, single-stranded DNA (ssDNA) gaps also characterize BRCA1 mutant cells and have been implicated in PARPi sensitivity. Here, unexpectedly, we find that RAD51 is essential and enriched in the chromatin of BRCA1-deficient cells, while additional deletion of 53BP1 alleviates this enrichment and dependency. The same pattern evolves along with PARPi resistance following loss of mediator of DNA damage checkpoint 1 (MDC1) or H2AX. Unlike 53BP1 loss, however, loss of MDC1 and H2AX in BRCA1-deficient cells does not restore RAD51 foci, further uncoupling HR from PARPi resistance. Collectively, we propose a model in which ssDNA gaps in BRCA1-deficient cells necessitate post-replicative RAD51 chromatin engagement for cell fitness, diverting RAD51 from other roles and revealing a targetable vulnerability.
Insights
BRCA1 mutant cancers exhibit RAD51 enrichment on chromatin, crucial for cell survival due to ssDNA gaps. Targeting this RAD51 engagement offers a new strategy for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- BRCA1 mutant cancers are homologous recombination (HR) deficient.
- This deficiency is linked to sensitivity to poly (ADP-ribose) polymerase inhibitors (PARPi).
- RAD51 foci are established biomarkers for PARPi response, but single-stranded DNA (ssDNA) gaps also play a role.
Purpose of the Study:
- To investigate the role of RAD51 in BRCA1-deficient cells.
- To explore the relationship between RAD51 chromatin enrichment, ssDNA gaps, and PARPi sensitivity.
- To understand the mechanisms underlying PARPi resistance.
Main Methods:
- Analysis of RAD51 foci and chromatin enrichment in BRCA1-deficient cells.
- Genetic manipulation involving deletion of 53BP1, MDC1, and H2AX.
- Assessment of poly (ADP-ribose) polymerase inhibitor (PARPi) resistance.
Main Results:
- RAD51 is essential and enriched in the chromatin of BRCA1-deficient cells.
- Loss of 53BP1 alleviates RAD51 enrichment and dependency.
- Loss of MDC1 or H2AX leads to PARPi resistance but does not restore RAD51 foci, uncoupling HR from resistance.
Conclusions:
- ssDNA gaps in BRCA1-deficient cells drive post-replicative RAD51 chromatin engagement for cell fitness.
- This RAD51 engagement represents a targetable vulnerability in BRCA1 mutant cancers.
- The findings challenge the direct correlation between RAD51 foci and PARPi response in certain contexts.
Related Concept Videos
Restarting Stalled Replication Forks
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Homologous Recombination
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

